Key Insights

Highlights

Success Rate

84% trial completion

Published Results

77 trials with published results (13%)

Research Maturity

315 completed trials (52% of total)

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 62/100

Termination Rate

9.9%

60 terminated out of 609 trials

Success Rate

84.0%

-2.5% vs benchmark

Late-Stage Pipeline

4%

26 trials in Phase 3/4

Results Transparency

24%

77 of 315 completed with results

Key Signals

77 with results84% success60 terminated

Data Visualizations

Phase Distribution

538Total
Not Applicable (131)
Early P 1 (4)
P 1 (318)
P 2 (59)
P 3 (22)
P 4 (4)

Trial Status

Completed315
Recruiting91
Unknown65
Terminated60
Active Not Recruiting43
Not Yet Recruiting15

Trial Success Rate

84.0%

Benchmark: 86.5%

Based on 315 completed trials

Clinical Trials (609)

Showing 20 of 20 trials
NCT05853575Phase 2Active Not RecruitingPrimary

Trial of Two Adagrasib Dosing Regimens in NSCLC With KRAS G12C Mutation (KRYSTAL 21)

NCT07737899Not ApplicableNot Yet Recruiting

Primary Palliative Care - a Feasibility Cluster Trial

NCT07636382Not ApplicableRecruitingPrimary

Simulation-Free Celiac Plexus Pain Ablation Using Stereotactic Body Radiotherapy in Patients With Cancer-Related Celiac Pain

NCT04657068Phase 1RecruitingPrimary

A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors

NCT05663710Phase 1RecruitingPrimary

Phase 1b/2 Study of Combination 177Lu Girentuximab Plus Cabozantinib and Nivolumab in Treatment naïve Patients With Advanced Clear Cell RCC

NCT05891171Phase 1Active Not RecruitingPrimary

Study of AB598 Monotherapy and Combination Therapy in Participants With Advanced Cancers

NCT06200155Phase 2Recruiting

Psilocybin-Assisted Psychotherapy in Patients With Advanced Cancer on Maintenance Therapy

NCT03785249Phase 1Active Not RecruitingPrimary

Phase 1/2 Study of MRTX849 in Patients With Cancer Having a KRAS G12C Mutation KRYSTAL-1

NCT07002203Phase 1Recruiting

Personalized Neoantigen Peptide Vaccines for Solid Tumors

NCT06771219Phase 1RecruitingPrimary

SLV-154 Treatment of Advanced Cancers

NCT05407844Not ApplicableEnrolling By Invitation

Community Health Worker Based Intervention to Improve Palliative Care

NCT05714553Phase 1TerminatedPrimary

NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours

NCT07426757Phase 1Recruiting

An Open-Label Study to Evaluate PF-07994525 in Participants With Advanced Cancers

NCT04864418Phase 1CompletedPrimary

AST-021p Study in Advanced Solid Tumors

NCT02711553Phase 2Active Not Recruiting

A Study of Ramucirumab (LY3009806) or Merestinib (LY2801653) in Advanced or Metastatic Biliary Tract Cancer

NCT07712237Not ApplicableCompletedPrimary

Web-Based Advance Care Planning for Patients With Advanced Cancer

NCT06117709Not ApplicableNot Yet RecruitingPrimary

Integrated Smartphone Technology to Alleviate Malignant Pain (I-STAMP) Testing

NCT01087554Phase 1Active Not RecruitingPrimary

Sirolimus or Everolimus or Temsirolimus and Vorinostat in Advanced Cancer

NCT06722014Not ApplicableCompleted

Integrating Pain-CBT Into an mHealth Analgesic Support Intervention for Patients With Chronic Pain From Advanced Cancers

NCT04406662Recruiting

Routine Evaluation of People Living With Cancer

Scroll to load more

Research Network

Activity Timeline